Blue Earth Diagnostics Ltd.
Radioactive imaging agent detects prostate cancer recurrence
This article was originally published in Start Up
Identifying the precise anatomical site of recurring prostate cancer determines how the disease is treated, however, the standard of care – a CT scan or MRI scan – accurately detects recurrent cancer only about 10% of the time. Blue Earth Diagnostics Ltd. believes its radioactive imaging agent, fluciclovine (18F), used in conjunction with a positron emission tomography scanner, could allow for a substantially higher detection rate.
You may also be interested in...
Israeli-based start-up Tyto Care markets TytoHome, a device that allows consumers to check their ears, breathing and temperature from home and share the findings with a clinician for remote diagnosis.
The race continues to heat up in the bioprinting space over which players will first reach the finish line in gaining approval for tissue and organ replacements. Research organizations and companies worldwide are in various states of development for these milestones in regenerative medicine, ranging from bioprinting skin to a mini human heart. But regulatory hurdles and quality testing could be formidable.
Market Intel: Large Providers Focus On Hemodialysis Home Care; New Incentive By Presidential Executive Order
Momentum is rising for patients with chronic kidney disease to be treated with hemodialysis in the comfort of their own home as opposed to traveling several days a week to a freestanding clinic. Manufacturers, government and payers are paving the way for a higher home-therapy adoption rate. That said, many patients remain unsuitable for home care and the large volume of water needed to operate hemodialysis can be logistically daunting.